Evidence map›Paper›PMID 23897772›Full record

ReviewAnnals of the rheumatic diseases2013

Value of biomarkers in osteoarthritis: current status and perspectives.

M Lotz, J Martel-Pelletier, C Christiansen, M-L Brandi, O Bruyère, R Chapurlat, J Collette, C Cooper, G Giacovelli, J A Kanis and 11 more

Erratum issuedOpen access · hybridAbstract readConsensus StatementReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Annals of the rheumatic diseases, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 140 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
140citing papers in PubMed, 5 pooled it
25.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

140 citing papers in PubMed, 5 syntheses or guidelines pooled it, 324 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. The clinical utility of imaging in osteoarthritis and its importance in future prediction of total hip replacement; a nested case-control study within the AGES-Reykjavik cohort.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2026
    Article
  19. Article
  20. Article

80 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

21 authors at 16 institutions in 10 countries.

M LotzDepartment of Molecular and Experimental Medicine, The Scripps Research Institute, , La Jolla, California, USA.
J Martel-Pelletier
C Christiansen
M-L Brandi
O Bruyère
R Chapurlat
J Collette
C Cooper
G Giacovelli
J A Kanis
M A Karsdal
V Kraus
W F Lems
I Meulenbelt
J-P Pelletier
J-P Raynauld
S Reiter-Niesert
R Rizzoli
L J Sandell
W E Van Spil
J-Y Reginster
Université de Montréal · CAUniversity of Liège · BENordic Bioscience (Denmark) · DKAmsterdam UMC Location VUmc · NLDuke University · USFederal Institute for Drugs and Medical Devices · DEGeneva College · USLeiden University Medical Center · NLScripps Research Institute · USUniversité Claude Bernard Lyon 1 · FRUniversity of Florence · ITUniversity of Mons · BEUniversity of Oxford · GBUniversity of Sheffield · GBUtrecht University · NLWashington University in St. Louis · US

Funding

Medical Research Council MC_U147585819Medical Research Council MC_U147585824Medical Research Council MC_UP_A620_1014Medical Research Council MC_UU_12011/1
6 · The paper itself

Abstract

Osteoarthritis affects the whole joint structure with progressive changes in cartilage, menisci, ligaments and subchondral bone, and synovial inflammation. Biomarkers are being developed to quantify joint remodelling and disease progression. This article was prepared following a working meeting of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis convened to discuss the value of biochemical markers of matrix metabolism in drug development in osteoarthritis. The best candidates are generally molecules or molecular fragments present in cartilage, bone or synovium and may be specific to one type of joint tissue or common to them all. Many currently investigated biomarkers are associated with collagen metabolism in cartilage or bone, or aggrecan metabolism in cartilage. Other biomarkers are related to non-collagenous proteins, inflammation and/or fibrosis. Biomarkers in osteoarthritis can be categorised using the burden of disease, investigative, prognostic, efficacy of intervention, diagnostic and safety classification. There are a number of promising candidates, notably urinary C-terminal telopeptide of collagen type II and serum cartilage oligomeric protein, although none is sufficiently discriminating to differentiate between individual patients and controls (diagnostic) or between patients with different disease severities (burden of disease), predict prognosis in individuals with or without osteoarthritis (prognostic) or perform so consistently that it could function as a surrogate outcome in clinical trials (efficacy of intervention). Future avenues for research include exploration of underlying mechanisms of disease and development of new biomarkers; technological development; the 'omics' (genomics, metabolomics, proteomics and lipidomics); design of aggregate scores combining a panel of biomarkers and/or imaging markers into single diagnostic algorithms; and investigation into the relationship between biomarkers and prognosis.

Indexed as

BiomarkersCartilage, ArticularDisease ProgressionHumansOsteoarthritisSynovial MembraneBiomarkersInflammationOsteoarthritisOutcomes research

Identifiers

PMID23897772
PMCPMC3812859
OpenAlexW2128468094

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.